Statins given to female patients are as effective in preventing the occurrence of cardiovascular events as they are for men, researchers from Boston and New York reported in the Journal of the American College of Cardiology. Cardiovascular events include stroke, heart attack, and angina. William J. Kostis, Ph.D., M.D., from Harvard Medical School, and team set out to determine what impact statins might have on reducing cardiovascular event risk in male and female patients. They gathered and analyzed data on 18 clinical trials which had gender-specific outcomes. A total of 141, 235 patients were involved in all the studies, of which 40, 275 were female - there were a total of 21, 468 cardiovascular events. They found that those who were prescribed (randomly) statins had a considerably lower risk of a cardiovascular event compared to those on a placebo, usual care, or low-dose statin therapy.
Study Of Genetic Regulation Of Metabolomic Biomarkers - Paths To Cardiovascular Diseases And Type 2 Diabetes
In a study into the genetic variance of human metabolism, researchers have identified thirty one regions of the genome that were associated with levels of circulating metabolites, i.e., small molecules that take part in various chemical reactions of human body. Many of the studied metabolites are biomarkers for cardiovascular disease or related disorders, thus the loci uncovered may provide valuable insight into the biological processes leading to common diseases. Laboratory tests used in the clinic typically monitor one or few circulating metabolites. The researchers at the Institute for Molecular Medicine Finland (FIMM) used a high throughput method called nuclear magnetic resonance (NMR) that can measure more than hundred different metabolites in one assay. This provides a much more in-depth picture of circulating metabolic compounds.
A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine. The cholesterol receptor offers a promising new target for anti-viral therapy, for which an approved drug may already exist, say the researchers, whose findings were reported online in advance of publication in Nature Medicine. An estimated 4.1 million Americans are infected with hepatitis C virus, or HCV, which attacks the liver and leads to inflammation, according to the National Institutes of Health. Most people have no symptoms initially and may not know they have the infection until liver damage shows up decades later during routine medical tests.
Statins are commonly prescribed to lower cholesterol, but a recent study suggest certain types of breast cancer may respond to treatment with statins. Led by Carol Prives of New York's Columbia University, the international team found when they treated breast cancer cells carrying a mutant p53 gene with statins, they stopped growing in the disorganized manner characteristic of tumors, and in some cases even died. However a lot more work needs to be done before the lab results translate into clinical success. The team writes about their findings in a report published online in the journal Cell on 20 January. In a statement to the press, Prives said they can't make any definite conclusions until they know more, but: "The data raises the possibility that we might identify subsets of patients whose tumors may respond to statins.
Furring of the arteries, atherosclerosis, is a leading cause of death across the world. Atherosclerosis leads to peripheral arterial disease, coronary heart disease, stroke and heart attacks. However, atherosclerosis is a sneaky killer - most people do not realize they have it until they have cardiovascular disease (CV). New research published in BioMed Central's open access journal BMC Medical Genomics has identified a set of biomarkers which can be used to test for early stage atherosclerosis. Researchers from the University of Virginia compared biomarkers isolated from monocytes (a type of white blood cells) in blood of patients with a family history of high cholesterol levels (familial hypercholesterolemia) to healthy controls. 363 genes were found to be differentially regulated (turned up or down) between the two groups.